🔎 Trials Near Me

Home › Chronic Lymphocytic Leukemia › Maryland

Chronic Lymphocytic Leukemia clinical trials in Maryland

23 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Maryland.

Cities in Maryland

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Oct 2, 2026 · NCT05724121

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • and 10 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 111, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05645107

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • American Oncology Partners of Maryland Pa, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • American Oncology Partners of Maryland Pa, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06846671

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  • National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 24, 2026 · NCT03986034

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • Center for Cancer and Blood Disorders ( Site 5439), Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05947851

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT01087333

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Johns Hopkins Asthma & Allergy Center, Baltimore
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Maryland Oncology Hematology, Silver Spring
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Maryland, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

  • National Institutes of Health Clinical Center, Bethesda
RecruitingEarly phase 1
Ages 18 to 100 · All sexes · Updated Aug 21, 2026 · NCT07428707

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • American Oncology Partners of Maryland, PA, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • The Center for Cancer and Blood Disorders-Bethesda, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07342478

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  • National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Jul 16, 2026 · NCT06364423

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institute of Health, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • American Oncology Partners, PA, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT06588478

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445, Bethesda
  • Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06428019

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.